PB-28
PB-28 is a synthetic cannabinoid and a derivative of the cannabinoid receptor agonist HU-210. It is known for its high affinity and selectivity for the CB2 receptor over the CB1 receptor, making it a significant compound in the study of cannabinoid receptor pharmacology.
Chemical Structure and Properties
PB-28 is chemically classified as a naphthoylindole derivative. Its structure includes a naphthalene ring attached to an indole moiety, which is a common feature among many synthetic cannabinoids. The specific modifications in PB-28 contribute to its unique receptor binding profile.
Pharmacology
PB-28 exhibits a high binding affinity for the CB2 receptor, which is primarily expressed in the immune system and associated with anti-inflammatory and immunomodulatory effects. Unlike many other synthetic cannabinoids, PB-28 has a significantly lower affinity for the CB1 receptor, which is predominantly found in the central nervous system and is responsible for the psychoactive effects of cannabinoids.
Receptor Selectivity
The selectivity of PB-28 for the CB2 receptor over the CB1 receptor makes it a valuable tool in research focused on the therapeutic potential of CB2 receptor agonists. This selectivity reduces the likelihood of psychoactive side effects, which are commonly associated with CB1 receptor activation.
Therapeutic Potential
Due to its selective action on the CB2 receptor, PB-28 is being investigated for its potential in treating various conditions, including inflammation, pain, and autoimmune diseases. Its ability to modulate the immune response without significant psychoactive effects makes it a promising candidate for further development.
Research and Development
Ongoing research is exploring the full pharmacological profile of PB-28, including its efficacy, safety, and potential therapeutic applications. Studies are also examining its interactions with other cannabinoid receptors and its effects on different biological systems.
See Also
References
External Links
Transform your life with W8MD's budget GLP-1 injections from $125.
W8MD offers a medical weight loss program to lose weight in Philadelphia. Our physician-supervised medical weight loss provides:
- Most insurances accepted or discounted self-pay rates. We will obtain insurance prior authorizations if needed.
- Generic GLP1 weight loss injections from $125 for the starting dose.
- Also offer prescription weight loss medications including Phentermine, Qsymia, Diethylpropion, Contrave etc.
NYC weight loss doctor appointments
Start your NYC weight loss journey today at our NYC medical weight loss and Philadelphia medical weight loss clinics.
- Call 718-946-5500 to lose weight in NYC or for medical weight loss in Philadelphia 215-676-2334.
- Tags:NYC medical weight loss, Philadelphia lose weight Zepbound NYC, Budget GLP1 weight loss injections, Wegovy Philadelphia, Wegovy NYC, Philadelphia medical weight loss, Brookly weight loss and Wegovy NYC
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD